NantKwest (NK) has risen sharply, recording gains of 11.7% in the past 4 weeks. However, the stock has corrected -3.11% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 11.27% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
NantKwest, Inc. is up 18.35% in the last 3-month period. Year-to-Date the stock performance stands at -58.68%. The stock has recorded a 20-day Moving Average of 0.53% and the 50-Day Moving Average is 6.55%.
NantKwest (NASDAQ:NK): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.07 and $7.03 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.16, notching a gain of 1.13% for the day. The total traded volume was 118,522 . The stock had closed at $7.08 on the previous day.
Also, Raymond James initiates coverage on NantKwest (NASDAQ:NK) The brokerage firm has issued a Market Perform rating on the shares. The rating by the firm was issued on June 2, 2016.
NantKwest, Inc., formerly Conkwest, Inc., is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Companys product candidates include aNK, haNK and taNK. The Companys aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus (HPV), induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16, a receptor that allows direct binding of NK cells to antibodies. The Companys taNK product candidate targets specific antigens on the surface of abnormal cells, including CD33, EGFR, HER2/neu, PDL1 and PSMA.